NCT03326921View on ClinicalTrials.gov

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

October 16, 2027

Study Completion Date

July 16, 2028

Conditions
Juvenile Myelomonocytic LeukemiaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Undifferentiated LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Myelodysplastic SyndromeRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmRefractory Myelodysplastic SyndromeAcute Undifferentiated LeukemiaMixed Phenotype Acute LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaAcute Biphenotypic LeukemiaChronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaMinimal Residual DiseaseRecurrent Chronic Myelomonocytic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaLeukemia
Interventions
BIOLOGICAL

CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

HighPass Bio, Inc.

UNKNOWN

collaborator

PromiCell Therapeutics, Inc.

UNKNOWN

lead

Fred Hutchinson Cancer Center

OTHER